has net revenues of $14.6bn for the second quarter (Q2) of 2022 as against $14bn in the year-ago quarter, indicating a 4.5% rise on a GAAP basis.
Net revenue surged by 6.1% on an operational basis during the quarter.
The GAAP diluted earnings per share (EPS) for the quarter ended 30 June grew by 21.4% to 0.51 from $0.42 in Q2 2021.
An 11.2% surge in adjusted diluted EPS of $3.37 was reported in Q2 this year against $3.03 in the prior-year quarter.
The immunology portfolio of the company delivered global net revenues of $7.21bn in this quarter, representing a surge of 17.8% on a reported basis and 19.2% on an operational basis.
鈥檚 Humira (adalimumab) generated a 9.6% rise in net revenues to $4.7bn in the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDuring the quarter, the company鈥檚 Skyrizi and Rinvoq generated combined global net revenues of $1.84bn.
The hematologic oncology and neuroscience portfolios delivered $1.65bn and $1.66bn in global net revenues, showing a decline of 9.1% and growth of 13.7%, respectively, on a reported basis.
Global net revenues generated by the aesthetics portfolio saw a 4.4% decline on a reported basis to $1.37bn.
AbbVie chairman and CEO Richard Gonzalez said: 鈥淲e delivered another strong quarter with substantial progress for our new products and indications.
鈥淚mportantly, Skyrizi and Rinvoq continued their impressive ramps and are on pace to deliver approximately $7.5bn in combined annual sales, underscoring their significant potential.
鈥淭he momentum of our business, combined with advances across our pipeline, continue to support AbbVie鈥檚 promising long-term outlook.鈥�
For the full-year 2022, the company has provided an adjusted diluted EPS guidance range of $13.78 to $13.98.聽
In February, AbbVie reported net revenues of nearly聽$56.2bn for the full year 2021聽on a GAAP basis.
